Evidence map›Paper›PMID 41256290›Full record

ArticleNAR molecular medicine2025

Characterization of

Andrea López-Martínez, Sergio Martín-González, Noemi Torres-Conde, Nahia Alcalá-Manso, Abdullah Al-Ani, Adolfo López de Munain, Anne Bigot, Kamel Mamchaoui, Gisela Nogales-Gadea, Virginia Arechavala-Gomeza

Abstract read
In one paragraph

Article in NAR molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea López-MartínezNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID https://orcid.org/0000-0003-4711-7495
Sergio Martín-GonzálezNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Noemi Torres-CondeNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Nahia Alcalá-MansoNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Abdullah Al-AniNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID https://orcid.org/0000-0003-4567-4837
Adolfo López de MunainGroup of Neurosciences, Department of Pediatrics and Neuroscience, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 20014 Donostia-San Sebastian, Spain.
Anne BigotMyoLine, Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013 Paris, France.
Kamel MamchaouiMyoLine, Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013 Paris, France.
Gisela Nogales-GadeaGrup de REcerca Neuromuscular de BAdalona (GRENBA), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID https://orcid.org/0000-0002-7414-212X
Virginia Arechavala-GomezaNucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID https://orcid.org/0000-0001-7703-3255

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy type I (DM1) is caused by CTG repeat expansions in the

Identifiers

PMID41256290
PMCPMC12430013

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.